Provectus Biopharmaceuticals, Inc.

Equities

PVCT

US74373P1084

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 03:42:01 2024-05-09 pm EDT			5-day change	1st Jan Change
0.1959 ^USD	+3.11%		+2.40%	+104.06%

Apr. 18	Provectus Biopharmaceuticals Announces Publication of Preclinical Data of Oral Administration of Provectus Rose	CI
Apr. 16	Provectus Biopharmaceuticals, Inc. Appoints Dominic Rodrigues as President	CI

Provectus Biopharmaceuticals Appoints Christopher Kaplan to its Strategic Advisory Board

September 22, 2014 at 06:00 am EDT

Provectus Biopharmaceuticals, Inc. announced that it has appointed Christopher Kaplan to its Strategic Advisory Board effective immediately. Mr. Kaplan is currently President of Cajetan, LLC. Prior to Cajetan, Mr. Kaplan spent two years with Boehringer Ingelheim as Senior Vice President and Chief Marketing Officer.

Latest news about Provectus Biopharmaceuticals, Inc.

Provectus Biopharmaceuticals Announces Publication of Preclinical Data of Oral Administration of Provectus Rose	Apr. 18	CI
Provectus Biopharmaceuticals, Inc. Appoints Dominic Rodrigues as President	Apr. 16	CI
Provectus Biopharmaceuticals, Inc. Appoints Ed Pershing as Chief Executive Officer	Apr. 16	CI
Provectus Biopharmaceuticals, Inc. Announces Presentation of Cancer Immunotherapy PV-10 Poster for HNSCC at AACR 2024 Annual Meeting	Apr. 11	CI
Provectus Biopharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Provectus Biopharmaceuticals, Inc. Announces Exclusive Worldwide License Agreement with University of Miami for Photodynamic Antimicrobial Treatment of Different Eye Infections with Rose Bengal Sodium	Mar. 27	CI
Provectus Biopharmaceuticals, Inc. Announces Management Changes	Mar. 26	CI
Provectus Biopharmaceuticals Provides Updated Data on Cancer Immunotherapy Pv-10 for Advanced Cutaneous Melanoma	Nov. 15	CI
Provectus Biopharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Provectus Biopharmaceuticals Provides Updated Data on Cancer Immunotherapy Pv-10 for Metastatic Uveal Melanoma	Nov. 13	CI
Provectus Biopharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Provectus Biopharmaceuticals Establishes Research Collaboration with University of Tennessee College of Veterinary Medicine to Investigate Pharmaceutical-Grade Small Molecule Immunotherapy Rose Bengal Sodium for Canine Soft Tissue Sarcomas	23-06-28	CI
Provectus Biopharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI
Provectus Biopharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt	23-03-29	CI
Provectus Biopharmaceuticals Announces New Data from Combination Therapy Trial of Small Molecule Cancer Immunotherapy PV-10(R) and Keytruda(R) for First-Line Stage III Melanoma at Melanoma Bridge 2022	22-12-01	CI
Provectus Biopharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-09	CI
Provectus Biopharmaceuticals Inc. Establishes Research Collaboration with University of Texas Medical Branch At Galveston	22-09-29	CI
Provectus Biopharmaceuticals Announces Exclusive License Option Agreement with Ophthalmic Biophysics Center of Bascom Palmer Eye Institute at University of Miami for Treatment of Eye Infections	22-09-21	CI
Provectus Biopharmaceuticals, Inc. announced that it expects to receive $5 million in funding	22-09-19	CI
Provectus Biopharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-11	CI
Provectus Biopharmaceuticals Establishes Research Collaboration with University of Nevada, Las Vegas to Investigate Small Molecule Immunotherapy Rose Bengal for Tissue Regeneration and Repair	22-07-19	CI
Provectus Biopharmaceuticals Presents Data from PV-10 Treatment of Metastatic Uveal Melanoma Patients in Two Oral Presentations at 2022 International Society of Ocular Oncology Congress	22-06-30	CI
Provectus Biopharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-12	CI
Provectus Biopharmaceuticals Announces Notice of Allowance of First U.S. Patent Application for Use of PV-10® Immunotherapy in Hematology	22-04-26	CI
Provectus Biopharmaceuticals Names Aru Narendran, MD, PhD to Scientific Advisory Board	22-04-14	CI

Chart Provectus Biopharmaceuticals, Inc.

Duration

Period

Chart Provectus Biopharmaceuticals, Inc.

More charts

Company Profile

Provectus Biopharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing immunotherapy medicines for different diseases that are based on a class of synthetic small-molecule immuno-catalysts called halogenated xanthenes (HXs). The Companyâs lead molecule is named rose bengal sodium (RBS). The Companyâs small molecule HX medical science platform comprises a range of different drug product candidates and preclinical pharmaceutical-grade RBS formulations using different concentrations and delivered by different routes of administration specific to each disease area and/or indication. The Companyâs HX medical science platform includes clinical development programs in oncology, dermatology, and ophthalmology; in vivo proof-of-concept drug discovery programs in oncology, hematology, wound healing, and animal health, and in vitro drug discovery programs in infectious diseases and tissue regeneration and repair.

Sector

Biotechnology & Medical Research

Calendar

2024-05-14 - Society for Investigative Dermatology Meeting

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
PROVECTUS BIOPHARMACEUTICALS, INC.	+104.06%	82.18M
VERTEX PHARMACEUTICALS INCORPORATED	+2.97%	108B
REGENERON PHARMACEUTICALS, INC.	+10.21%	104B
ARGENX SE	+1.57%	22.33B
BIONTECH SE	-12.77%	22.19B
GENMAB A/S	-7.05%	18.69B
WUXI APPTEC CO., LTD.	-37.64%	17.74B
BEIGENE, LTD.	-6.50%	17.64B
NEUROCRINE BIOSCIENCES, INC.	+6.00%	14.05B
SAREPTA THERAPEUTICS, INC.	+37.20%	12.51B

Bio Therapeutic Drugs